世界卫生组织（WHO）于2025年9月22-25日召开了2025年南半球流感疫苗组分会议，经过对全球流感病毒流行病学、病原学及疫苗血清学分析，于26日公布疫苗组分。

用于鸡胚疫苗生产的三价流感疫苗组分如下：

• an A/Missouri/11/2025 (H1N1)pdm09-like virus; ​

• an A/Singapore/GP20238/2024 (H3N2)-like virus; and ​

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

用于细胞疫苗、重组蛋白疫苗或核酸疫苗生产的三价流感疫苗组分如下：

• an A/Missouri/11/2025 (H1N1)pdm09-like virus; ​

• an A/Sydney/1359/2024 (H3N2)-like virus; and ​

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

与2023年9月以来世卫组织此前四次建议一致*，世卫组织流感疫苗组分咨询委员会仍认为，不再需要纳入B/Yamagata系疫苗组分。B/Yamagata系疫苗组分将不再更新。（Consistent with previous four WHO recommendations since September 2023, it remains the opinion of the WHO influenza vaccine composition advisory committee that the inclusion of a B/Yamagata lineage antigen is no longer warranted. There will no longer be updated recommendations for the B/Yamagata lineage component.）

^* https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations​

世界卫生组织推荐2026年南半球流感疫苗组分原文链接：https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2026-southern-hemisphere-influenza-season